Skip to main content

Advertisement

SpringerLink
Log in

Cancer of the gastroesophageal junction: Current therapy options

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Active chemotherapy agents in metastatic adenocarcinoma of the esophagus include taxanes (docetaxel or paclitaxel), 5-fluorouracil, irinotecan, platinum drugs (including cisplatin, oxaliplatin, and carboplatin), and anthracyclines. Conventional chemotherapy combines infusional 5-fluorouracil with cisplatin. The addition of a third drug to this backbone results in greater toxicity and only marginal improvements in outcome. Alternative and potentially better-tolerated chemotherapy involves two-drug regimens, combining 5-fluorouracil with a taxane or irinotecan, or combining a platinum drug with irinotecan or a taxane. Although preoperative chemotherapy improves survival compared with surgery alone, the addition of radiation therapy to chemotherapy preoperatively improves rates of curative resection, reduces local tumor recurrence, and achieves a significant rate of pathologic complete response. Combined preoperative chemotherapy and concurrent radiotherapy is the preferred preoperative strategy for locally advanced adenocarcinoma of the esophagus. Survival is improved with postoperative chemotherapy and radiotherapy if none has been delivered preoperatively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2006. CA Cancer J Clin 2006, 56:106–130.

    Article  PubMed  Google Scholar 

  2. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049–2053.

    Article  PubMed  CAS  Google Scholar 

  3. Lagergren J, Bergstrom R, Lindgren A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825–831.

    Article  PubMed  CAS  Google Scholar 

  4. Engel LS, Chow W, Vaughan TL, et al.: Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003, 95:1404–1413.

    PubMed  Google Scholar 

  5. Spechler, JS: Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992, 326:786–792.

    Article  PubMed  CAS  Google Scholar 

  6. Spechler J: Clinical practice. Barrett's esophagus. N Engl J Med 2002, 346:836–842.

    Article  PubMed  Google Scholar 

  7. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47–56.

    Article  PubMed  CAS  Google Scholar 

  8. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005, 90:139–146.

    Article  PubMed  Google Scholar 

  9. Orringer MB, Marshall B, Iannettoni MD: Transhiatal esophagectomy for treatment of benign and malignant esophageal disease. World J Surg 2001, 25:196–203.

    Article  PubMed  CAS  Google Scholar 

  10. Skinner DB: En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 1983, 85:59–71.

    PubMed  CAS  Google Scholar 

  11. Hulscher JBF, van Sandick JW, de Boer AGEM, et al.: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662–1669.

    Article  PubMed  Google Scholar 

  12. Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979–1984.

    Article  PubMed  CAS  Google Scholar 

  13. Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000, 18:2648–2657.

    PubMed  CAS  Google Scholar 

  14. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261–267.

    PubMed  CAS  Google Scholar 

  15. Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002, 20:1996–2004.

    Article  PubMed  CAS  Google Scholar 

  16. Moiseyenko VM, Ajani J, Tjulandin SA, et al.: Final results of randomized controlled phase III trial (TAX 325) comparing docetaxel combined with cisplatin and 5-fluorouracil to CF in patients with metastatic gastric adenocarcinoma [abstract 4002]. Proc Am Soc Clin Oncol 2005, 23:308.

    Google Scholar 

  17. Roth DA, Maibach R, Falk S, et al.: Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 2004, 22. Abstract 4020.

  18. Dank M, Zaluski J, Barone C, et al.: Randomized phase 3 trial of irinotecan + 5FU/folinic acid vs CDDP + 5FU in first line advanced gastric cancer patients [abstract 4003]. Proc Am Soc Clin Oncol 2005, 23:308.

    Google Scholar 

  19. Sumpter K, Harper-Wynne C, Cunningham D, et al.: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005, 92:1976–1983.

    Article  PubMed  CAS  Google Scholar 

  20. Clark PI: Medical research council randomized trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus. Lancet 2002, 359:1727–1733.

    Article  Google Scholar 

  21. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract 4001]. Proc Am Soc Clin Oncol 2005, 23:3085. Preoperative chemotherapy improves survival when added to surgery for esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma. However, rates of curative resection are not significantly improved, and pathologic complete responses rarely are achieved.

    Google Scholar 

  22. Armanios M, Xu R, Forastiere A, et al.: Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 2004, 22:4495–4499.

    Article  PubMed  CAS  Google Scholar 

  23. Herskovic A, Martz K, Al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593–1598.

    Article  PubMed  CAS  Google Scholar 

  24. Cooper J, Guo MD, Herskovic A, et al.: Chemoradiotherapy of locally advanced esophageal cancer: longterm follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623–1627.

    Article  PubMed  CAS  Google Scholar 

  25. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305–313.

    PubMed  CAS  Google Scholar 

  26. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Eng J Med 1996, 335:462–467.

    Article  CAS  Google Scholar 

  27. Burmeister B, Walpole E, Burmeister E, et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659–668. Preoperative combined chemotherapy and concurrent radiotherapy achieve pathologic complete responses, enhance rates of curative resection, and reduce local recurrence compared with surgery alone. However, the phase III trials are small and underpowered, and collectively do not demonstrate an improvement in survival compared with surgery alone, despite trends toward improved survival after preoperative chemoradiotherapy.

    Article  PubMed  Google Scholar 

  28. Krasna M, Tepper J, Niedzwicki D, et al.: Trimodality therapy is superior to surgery alone in esophageal cancer: results of CALGB 9781 [abstract 4]. Paper presented at the 2006 Gastrointestinal Cancers Symposium. San Francisco, CA, January 26–28, 2006. Preoperative combined chemotherapy and concurrent radiotherapy achieve pathologic complete responses, enhance rates of curative resection, and reduce local recurrence compared with surgery alone. However, the phase III trials are small and underpowered, and collectively do not demonstrate an improvement in survival compared with surgery alone, despite trends toward improved survival after preoperative chemoradiotherapy.

  29. Kaklamanos I, Walker G, Ferry K, et al.: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003, 10:754–761.

    Article  PubMed  Google Scholar 

  30. Macdonald J, Smalley S, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730.

    Article  PubMed  CAS  Google Scholar 

  31. Coia LR, Minsky BD, John MJ, et al.: The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992–1994 Patterns of Care Study. Cancer 1999, 85:2499–2505.

    Article  PubMed  CAS  Google Scholar 

  32. Bedenne L, Bouche MP: Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002, 20:130a.

    Google Scholar 

  33. Stahl M, Stuschke M, Lehmann N: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310–2317.

    Article  PubMed  Google Scholar 

  34. Swisher S, Wynn P, Putnam J, et al.: Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002, 123:175–183.

    Article  PubMed  Google Scholar 

  35. Minsky BD, Neuberg D, Kelsen DP, et al.: Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999, 43:517–523.

    Article  PubMed  CAS  Google Scholar 

  36. Minsky BD, Berkey B, Kelsen DK, et al.: Preliminary results of intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: standard vs. high dose radiation therapy. J Clin Oncol 2002, 20:1167–1174.

    Article  PubMed  CAS  Google Scholar 

  37. Gaspar LE, Winter K, Kocha WI, et al.: A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000, 88:988–995.

    Article  PubMed  CAS  Google Scholar 

  38. Bains MS, Stojadinovic A, Minsky B, et al.: A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002, 124:270–277.

    Article  PubMed  CAS  Google Scholar 

  39. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058–3065.

    PubMed  CAS  Google Scholar 

  40. Adelstein DJ, Rice TW, Rybicki LA, et al.: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000, 18:2032–2039.

    PubMed  CAS  Google Scholar 

  41. Blanke CD, Choy H, Teng M, et al.: Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 1999, 9:43–52.

    PubMed  CAS  Google Scholar 

  42. Urba S, Orringer M, Iannettoni M, et al.: Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003, 98:2177–2183.

    Article  PubMed  CAS  Google Scholar 

  43. Brenner B, Ilson D, Minsky B, et al.: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004, 22:45–52.

    Article  PubMed  CAS  Google Scholar 

  44. Safran H, Gaissert H, Akerman P, et al.: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001, 19:1–7.

    Article  PubMed  CAS  Google Scholar 

  45. Wright CD, Wain JC, Lynch TJ, et al.: Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 1997, 114:811–815.

    Article  PubMed  CAS  Google Scholar 

  46. Weiner L, Colarusso P, Goldberg M, et al.: Combinedmodality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 1997, 24(Suppl 19):93–95.

    CAS  Google Scholar 

  47. Meluch AA, Hainsworth JD, Gray JR, et al.: Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999, 5:84–91.

    PubMed  CAS  Google Scholar 

  48. Roof KS, Coen J, Lynch TJ, et al.: Neo adjuvant radiation, cisplatin 5-FU, +/- paclitaxel in locally advanced esophageal cancer. Proc Am Soc Clin Oncol 2004, 22. Abstract 4042.

  49. Ajani JA, Komaki R, Walsh GL, et al.: CPT-11 plus cisplatin as induction chemotherapy followed by chemoradiotherapy in resectable carcinoma of the esophagus and GE junction. Proc Am Soc Clin Oncol 2001, 20. Abstract 521.

  50. Mauer AM, Haraf DC, Ferguson MK, et al.: Docetaxelbased combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 2000, 19. Abstract 954.

    Google Scholar 

  51. Ilson D, Bains M, Kelsen D, et al.: Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003, 21:2926–2932.

    Article  PubMed  CAS  Google Scholar 

  52. Enzinger P, Mamon H, Choi N, et al.: Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Am Soc Clin Oncol 2004, 22. Abstract 35.

  53. Sarbia M, Stahl M, Fink U, et al.: Expression of apoptosisregulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998, 4:2991–2997.

    PubMed  CAS  Google Scholar 

  54. Kishi KDY, Miyata H, Yano, et al.: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002, 89:597–603.

    Article  PubMed  CAS  Google Scholar 

  55. Downey RJ, Akhurst T, Ilson D, et al.: Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2005, 21:428–432.

    Article  Google Scholar 

  56. Flamen P, Van Cutsem E, Lerut A, et al.: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361–368.

    Article  PubMed  CAS  Google Scholar 

  57. Gibson MK, Abraham SC, Wu TT, et al.: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003, 9:6461–6468.

    PubMed  CAS  Google Scholar 

  58. Walsh TN, Grannell M, Mansoor S: Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 2002, 17(Suppl):S172-S175.

    Article  PubMed  Google Scholar 

  59. Harpole DH Jr, Moore MB, Herndon JE 2nd, et al.: The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001, 7:562–569.

    PubMed  Google Scholar 

  60. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998, 83:7–18.

    Article  PubMed  CAS  Google Scholar 

  61. Kanamoto A, Kato H, Tachimori Y, et al.: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999, 72:94–98.

    Article  PubMed  CAS  Google Scholar 

  62. Hickey K, Grehan D, Reid IM, et al.: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74:1693–1698.

    Article  PubMed  CAS  Google Scholar 

  63. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S9-S15.

    Article  PubMed  CAS  Google Scholar 

  64. Hirai T, Kuwahara M, Yoshida K, et al.: Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus 1998, 11:221–225.

    PubMed  CAS  Google Scholar 

  65. Itakura Y, Sasano H, Shiga C, et al.: Epidermal growth factor receptor over-expression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74:795–804.

    Article  PubMed  CAS  Google Scholar 

  66. Kitagawa Y, Ueda M, Ando N, et al.: Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996, 2:909–914.

    PubMed  CAS  Google Scholar 

  67. Ito T, Kaneko K, Makino R, et al.: Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001, 36:303–311.

    Article  PubMed  CAS  Google Scholar 

  68. Dragovich T, McCoy S, Urba S, et al.: SWOG 0127: phase II trial of erlotinib in GEJ and gastric adenocarcinoma [abstract 49]. Paper presented at the 2005 Gastrointestinal Cancers Symposium. Hollywood, FL, January 27–29, 2005.

  69. Tew W, Shah M, Schwartz G, et al.: Phase II trial of erlotinib for second line treatment in advanced esophageal cancer [abstract 5]. Paper presented at the 2005 Gastrointestinal Cancers Symposium. Hollywood, FL, January 27–29, 2005.

  70. al-Kasspooles M, Moore JH, Orringer MB, Beer DG: Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993, 54:213–219.

    Article  PubMed  CAS  Google Scholar 

  71. Safran H, DiPetrillo T, Nadeem A, et al.: Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004, 22:670–677.

    Article  PubMed  CAS  Google Scholar 

  72. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4–25.

    Article  PubMed  CAS  Google Scholar 

  73. Chen HX: Expanding the clinical development of bevacizumab. Oncologist 2004, 9(Suppl 1):27–35.

    Article  PubMed  CAS  Google Scholar 

  74. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  75. Shih CH, Ozawa S, Ando N, et al.: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000, 6:1161–1168.

    PubMed  CAS  Google Scholar 

  76. Kitadai Y, Haruma K, Tokutomi T, et al.: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998, 4:2195–2200.

    PubMed  CAS  Google Scholar 

  77. Inoue K, Ozeki Y, Suganuma T, et al.: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997, 79:206–213.

    Article  PubMed  CAS  Google Scholar 

  78. Kleespies A, Guba M, Jauch KW, Bruns CJ: Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004, 87:95–104.

    Article  PubMed  CAS  Google Scholar 

  79. Govindan R, Fineberg R, McLeod H, et al.: A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): updated results from the Hoosier Oncology Group (HOG) study. Proc Am Soc Clin Oncol 2004, 22. Abstract 4052.

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, USA

    David H. Ilson MD, PhD

  2. Weill-Cornell University Medical College, 1275 York Avenue, 10021, New York, NY, USA

    David H. Ilson MD, PhD

Authors
  1. David H. Ilson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ilson, D.H. Cancer of the gastroesophageal junction: Current therapy options. Curr. Treat. Options in Oncol. 7, 410–423 (2006). https://doi.org/10.1007/s11864-006-0009-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0009-6

Keywords

Search

Navigation